- Home
- BDJ vs TVTX Comparison
BDJ vs TVTX Comparison
Compare BDJ & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDJ | TVTX |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BDJ | TVTX |
|---|---|---|
| Price | $9.53 | $35.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $37.21 |
| AVG Volume (30 Days) | 561.6K | ★ 1.9M |
| Earning Date | 01-01-0001 | 02-19-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $435,826,000.00 |
| Revenue This Year | N/A | $120.02 |
| Revenue Next Year | N/A | $37.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 114.22 |
| 52 Week Low | $6.91 | $12.91 |
| 52 Week High | $8.66 | $42.13 |
Technical Indicators
Market Signals| Indicator | BDJ | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 49.11 |
| Support Level | $9.26 | $34.50 |
| Resistance Level | $9.54 | $40.75 |
| Average True Range (ATR) | 0.08 | 2.22 |
| MACD | 0.01 | -0.27 |
| Stochastic Oscillator | 93.93 | 25.93 |
Price Performance
Historical ComparisonAbout BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.